Apriem Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Apriem Advisors’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,750	Closed	-$24K	–	321
2018 Q2	$24K	Buy	+3,750	New	+$23.7K	0.01%	328
2017 Q2	–	Sell	-3,000	Closed	-$24K	–	447
2017 Q1	$24K	Hold	3,000	–	–	0.01%	321
2016 Q4	$27K	Hold	3,000	–	–	0.01%	307
2016 Q3	$28K	Hold	3,000	–	–	0.01%	285
2016 Q2	$31K	Buy	3,000 +500	+20%	+$4.58K	0.01%	284
2016 Q1	$23K	Buy	2,500 +750	+43%	+$6.7K	0.01%	290
2015 Q4	$16K	Sell	1,750 -1,250	-42%	-$13.7K	0.01%	328
2015 Q3	$38K	Sell	3,000 -1,250	-29%	-$15.5K	0.01%	225
2015 Q2	$47K	Buy	4,250 +750	+21%	+$8.28K	0.02%	224
2015 Q1	$40K	Buy	3,500 +1,000	+40%	+$10.6K	0.01%	227
2014 Q4	$25K	Sell	2,500 -1,000	-29%	-$10.5K	0.01%	266
2014 Q3	$37K	Hold	3,500	–	–	0.01%	241
2014 Q2	$30K	Hold	3,500	–	–	0.01%	240
2014 Q1	$31K	Hold	3,500	–	–	0.01%	258
2013 Q4	$29K	Hold	3,500	–	–	0.01%	257
2013 Q3	$26K	Hold	3,500	–	–	0.01%	257
2013 Q2	$26K	Buy	+3,500	New	+$25.6K	0.01%	251

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $355M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Apriem Advisors's RDY Position: Q3 2018 in Review

Apriem Advisors sold out of Dr. Reddy's Laboratories (RDY) in Q3 2018, closing a stake of 3,750 shares — an estimated $24K sold.

Apriem Advisors first reported a position in RDY in Q2 2013 and held it in 17 quarters. The position peaked at $47K in Q2 2015. 125 funds tracked by Wall St. Rank hold RDY as of Q3 2018.

Apriem Advisors reported no remaining Dr. Reddy's Laboratories position as of Q3 2018 after selling out during the quarter.
Apriem Advisors sold 3,750 Dr. Reddy's Laboratories shares in Q3 2018, an estimated $24K.
Apriem Advisors first reported a position in Dr. Reddy's Laboratories in Q2 2013 and held it in 17 quarters.
Apriem Advisors's Dr. Reddy's Laboratories position peaked at $47K in Q2 2015.
125 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2018.

Based on Apriem Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.